VBIV VBI Vaccines Inc Total Asset Value of Company

VBIV (vbivaccines.com) - company brandmark

VBI Vaccines Inc. (VBIV) has developed a unique suite of drugs based on eVLP technologies, maintaining its hold on medical centers through patent protection. However, the company is currently undergoing liquidation due to the collapse of partnerships, which has led to the sale of its assets. This chart reflecting the price action of total assets records the figure at 0.00. Simultaneously, the business is implementing ESG standards, investing funds into eco-friendly waste recycling and production energy efficiency.

VBIV (VBI Vaccines) Company Total Assets history from 07/04/2022 to 08/17/2024

Analytical breakdowns and data insights for company vbivaccines.com (VBIV)

- share price and consensus valuation forecast:
Price Chart VBI Vaccines|VBIV - Price Target Chart
- market capitalization data:
Market Valuation VBI Vaccines|VBIV - Enterprise Value
- issuer book value statistics:
Accounting Value of a Share VBI Vaccines|VBIV - Book Capitalization|Market Capitalization to Book Value Ratio vbivaccines.com|VBIV - Aggregate Company Assets
- debt burden and liquidity indicators:
All Debt to Shareholders' Equity Ratio VBI Vaccines Inc.|VBIV - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio VBI Vaccines|VBIV - Company Aggregate Debts|Debts to Book Capitalization VBI Vaccines|VBIV - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings VBI Vaccines|Quick Liquidity vbivaccines.com
- net income and valuation multiples indicators:
VBIV - Net Profit
Fundamental valuation:VBI Vaccines Inc.
Manufactured products of VBI Vaccines, Inc.

For VBI Vaccines Inc. (VBIV), in the liquidation phase, the total value of resources serves as an indicator of residual capital, where the asset value based on ROA, calculated reversely through profitability, reflects the rate of contraction of the asset base. This metric measures the total amount of liabilities and equity, signaling to the investor the pace of the operational structure's dissolution and the final value of assets in the event of bankruptcy.

Key competitors

GILD (gilead.com) - Aggregate Company Assets|Aggregate Company Assets cidara.com|Novavax Inc - Total Asset Value of Company|Company Total Assets CVAC|VALN (Valneva Vaccines) - Aggregate Asset Value|Company Total Assets VIR (Vir Biotechnology, Inc.)|Company Total Assets siga.com SIGA|EBS - Aggregate Company Assets|Aggregate Asset Value AVIR (Atea Pharma)|invivyd.com (IVVD) - Aggregate Company Assets|Cumulative Company Assets Enanta Pharmaceuticals, Inc|INO (Inovio Pharmaceuticals) - Company Total Assets|Company Total Assets hillevax.com|Cumulative Company Assets KLRS (Kalaris Therapeutics)|DYAI (dyadic.com) - Aggregate Asset Value|NanoViricides - Cumulative Company Assets|Talphera Corporation - Aggregate Company Assets|Cocrystal Pharma, Inc. - Company Total Assets|Company Total Asset Base Traws Pharma, Inc. TRAW|dwtx.com (DWTX) - Aggregate Company Assets|Qualigen Therapeutics Inc - Aggregate Asset Value|Cumulative Company Assets ALVR|Company Total Assets Virios|Aggregate Company Assets Vaxart, Inc. (VXRT)